Open Access<p>Use of Immunomodulating Drugs and Risk of Cutaneous Melanoma: A Nationwide Nested Case-Control Study</p>
Author(s) -
Leon A M Berge,
Bettina Kulle Andreassen,
Jo Steinson Stenehjem,
Trond Heir,
Øystein Karlstad,
Asta Juzeniene,
Reza Ghiasvand,
Inger Kristin Larsen,
Adèle C. Green,
Marit B. Veierød,
Trude Eid Robsahm
Publication year - 2020
Publication title -
clinical epidemiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.868
H-Index - 58
ISSN - 1179-1349
DOI - 10.2147/clep.s269446
Subject(s) - medicine , medical prescription , relative risk , confidence interval , population , melanoma , cancer registry , skin cancer , cancer , oncology , pharmacology , environmental health , cancer research
Cutaneous melanoma is among the fastest growing malignancies in Norway and ultraviolet radiation (UVR) exposure is the primary environmental risk factor. Immunomodulating drugs can increase skin photosensitivity and suppress immune responses, and by such mechanisms influence melanoma risk. We, therefore, aimed to examine the associations between use of immunomodulating drugs and melanoma risk, at a nationwide population level.